Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Proline-rich gamma-carboxyglutamic acid protein 1 (PRRG1)
- Target
- PRRG1
- Molecular classification
- Other (vitamin K-dependent, single-pass transmembrane protein with Gla domain; not a standard receptor, enzyme, ion channel, transporter, or transcription factor)
01
Overview
Proline-rich gamma-carboxyglutamic acid protein 1 (PRRG1) is a vitamin K-dependent, gamma-carboxyglutamic acid (Gla) containing single-pass transmembrane protein. It features a Gla domain at the N-terminus, which requires post-translational gamma-carboxylation by a vitamin K-dependent gamma-carboxylase, and a proline-rich C-terminus containing signaling and cytoskeletal motifs (PPXY and PXXP). PRRG1 is highly expressed in neural tissues, especially the spinal cord, but its precise physiological role is not fully defined. It is not classified as a receptor, enzyme, transporter, or key druggable therapeutic target. Disease associations mainly involve rare hereditary deficiencies of vitamin K-dependent clotting factors, and there are currently no known drugs, biomarkers, or therapeutic safety concerns directly related to PRRG1.
- Other names
- Proline-rich and Gla domain 1PRRG1PRGP1Transmembrane gamma-carboxyglutamic acid protein 1Proline-rich Gla protein 1TMG1Proline-rich Gla (G-carboxyglutamic acid) 1Proline-rich gamma-carboxyglutamic acid protein 1Proline-rich Gla (G-carboxyglutamic acid) polypeptide 1
02
Mechanism of action
Not applicable, as there are no known drugs directly targeting PRRG1
03
Biological functions
Calcium ion binding (via Gla domain)Possibly involved in intracellular signaling or cytoskeletal interactions (proline-rich motifs are common in signaling/cytoskeletal proteins)Specific function remains not fully elucidated; it is highly expressed in the spinal cord
04
Disease associations
Hereditary combined deficiency of vitamin K-dependent clotting factorsVitamin K-dependent clotting factors, combined deficiency, 1No direct association with common therapeutic areas such as cancer, inflammation, neurodegenerative disease, cardiovascular disease, or infection
Beyond the preview
Go deeper on Proline-rich gamma-carboxyglutamic acid protein 1 (PRRG1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Proline-rich gamma-carboxyglutamic acid protein 1 (PRRG1).